NCT00524810View on ClinicalTrials.gov

Liposomal Doxorubicin and Docetaxel in Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Pegylated liposomal doxorubicin

Caelyx 30 mg/m² day 1 every 3 weeks

DRUG

Docetaxel

Taxotere 75 mg/m² day 2 every 3 weeks

Trial Locations (1)

75004

Hôpital HOTEL DIEU, Paris

All Listed Sponsors
lead

ARCAGY/ GINECO GROUP

OTHER

NCT00524810 - Liposomal Doxorubicin and Docetaxel in Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter